The Emory‐Sage‐SGC TREAT‐AD Center: Tool and probe development for emerging targets in Alzheimer’s Disease

Alzheimer’s disease is the most common form of dementia and there is currently no effective therapy for either treatment or prevention. With repeated failure in DRUG DEVELOPMENT across industry and demonstrated heterogeneity in biological and genetic components of the disease, there is a need to evaluate a broad range of therapeutic hypotheses for target prioritization. The Emory‐Sage‐SGC TREAT‐AD Center (https://treatad.org) is generating and openly distributing validated experimental tools necessary to test target predictions generated through sequence‐based characterization of human disease state. We believe that these tools and reagents, including chemical and biological probes that target the multifaceted dysregulation in the brains of AD patients will advance the discovery of potential drug targets for AD.